Literature DB >> 16236086

Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control.

C J Bailey1, S Del Prato, D Eddy, B Zinman.   

Abstract

In type 2 diabetes, the onset and progression of complications is significantly delayed by improving glycaemic control. However, the proportion of patients reaching and sustaining guideline recommendations for glycaemic targets remains unacceptably low. Recent clinical trials and predictive physiologically based mathematical simulations (Archimedes model) indicate that benefits can be enhanced with earlier intervention and timely achievement of glycaemic targets. This article reviews the evidence for early intervention, showing that intensive approaches, including earlier introduction of combination therapy, allow more patients to achieve glycaemic targets and hence reduce complications and delay disease progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16236086     DOI: 10.1111/j.1742-1241.2005.00675.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  13 in total

1.  Comparative effectiveness of early versus delayed metformin in the treatment of type 2 diabetes.

Authors:  Robert J Romanelli; Sukyung Chung; Jia Pu; Vani Nimbal; Beinan Zhao; Latha Palaniappan
Journal:  Diabetes Res Clin Pract       Date:  2015-01-21       Impact factor: 5.602

Review 2.  Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management.

Authors:  S Del Prato; J LaSalle; S Matthaei; C J Bailey
Journal:  Int J Clin Pract       Date:  2010-02       Impact factor: 2.503

3.  A follow-up study of the occurrence and consequences of HbA1c measurements in an unselected cohort of non-pharmacologically treated patients with Type 2 diabetes.

Authors:  Jette Kolding Kristensen; Henrik Stoevring
Journal:  Scand J Prim Health Care       Date:  2008       Impact factor: 2.581

Review 4.  Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses.

Authors:  D S Lasserson; P Glasziou; R Perera; R R Holman; A J Farmer
Journal:  Diabetologia       Date:  2009-07-31       Impact factor: 10.122

5.  Bariatric surgery: an IDF statement for obese Type 2 diabetes.

Authors:  J B Dixon; P Zimmet; K G Alberti; F Rubino
Journal:  Diabet Med       Date:  2011-06       Impact factor: 4.359

6.  Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.

Authors:  Lizheng Shi; Xin Ye; Mei Lu; Eric Q Wu; Hari Sharma; Darren Thomason; Mengxi Zhang; Yao Wang; Vivian A Fonseca
Journal:  Diabetes Ther       Date:  2015-07-23       Impact factor: 2.945

7.  The substantial burden of non-communicable diseases and HIV-comorbidity amongst adults: Screening results from an integrated HIV testing services clinic for adults in Soweto, South Africa.

Authors:  Kathryn L Hopkins; Khuthadzo E Hlongwane; Kennedy Otwombe; Janan Dietrich; Mireille Cheyip; Jacobus Olivier; Heidi van Rooyen; Tanya Doherty; Glenda E Gray
Journal:  EClinicalMedicine       Date:  2021-07-14

8.  Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.

Authors:  C J Östgren; J Sundström; B Svennblad; L Lohm; P M Nilsson; G Johansson
Journal:  Diabet Med       Date:  2013-03-13       Impact factor: 4.359

9.  Kidney-targeted transplantation of mesenchymal stem cells by ultrasound-targeted microbubble destruction promotes kidney repair in diabetic nephropathy rats.

Authors:  Yi Zhang; Chuan Ye; Gong Wang; Yunhua Gao; Kaibin Tan; Zhongxiong Zhuo; Zheng Liu; Hongmei Xia; Dan Yang; Peijing Li
Journal:  Biomed Res Int       Date:  2013-05-27       Impact factor: 3.411

10.  Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial.

Authors:  A R Chacra; G H Tan; A Apanovitch; S Ravichandran; J List; R Chen
Journal:  Int J Clin Pract       Date:  2009-07-15       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.